Close Menu

NanoString

NanoString said its revenues were driven by meeting collaboration milestones, demand for instruments, and consumables pull-through.

The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.

The insurer is the latest to provide coverage for NanoString's gene expression-based breast cancer recurrence risk test.

Noridian said it has identified new data that will "significantly impact" its proposed policy on biomarker tests for guiding adjuvant chemotherapy decisions.

Noridian proposes to cover several biomarker tests for guiding chemotherapy decisions for breast cancer patients with node-negative disease but not when it's node positive.

Aetna considers the test "medically necessary" and the decision opens the door for 19 million people to access the risk classifier test.

Revenue increased based on growth in the consumables and new collaboration revenue streams, while instrument sales slipped.

The Alameda, California-based firm is embarking on an internal validation study for its lung cancer liquid biopsy and is seeking to build a CLIA-certified lab.

The partners will jointly develop and commercialize gene expression assays to predict response to cancer immunotherapy, based on the nCounter platform.

The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.